155 related articles for article (PubMed ID: 21154139)
41. Superbugs and Superdrugs-SMi's 12th annual conference--Overcoming resistance. 17-18 March 2010, London, UK.
Oni A
IDrugs; 2010 May; 13(5):314-6. PubMed ID: 20432187
[TBL] [Abstract][Full Text] [Related]
42. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
43. Cancer vaccines: between the idea and the reality.
Finn OJ
Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
[TBL] [Abstract][Full Text] [Related]
44. Is vaccine therapy a renewed strategic approach for non-small-cell lung cancer therapy?
Rossi A
Expert Rev Vaccines; 2013 Jan; 12(1):5-7. PubMed ID: 23256734
[No Abstract] [Full Text] [Related]
45. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
Luo Y; Zhou H; Mizutani M; Mizutani N; Liu C; Xiang R; Reisfeld RA
Cancer Res; 2005 Apr; 65(8):3419-27. PubMed ID: 15833877
[TBL] [Abstract][Full Text] [Related]
46. [Research progress on DNA tumor vaccine].
Xue ZW; Zhou XL
Zhongguo Yi Miao He Mian Yi; 2010 Apr; 16(2):183-6. PubMed ID: 20575277
[TBL] [Abstract][Full Text] [Related]
47. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
48. GTCBio's Precision Medicine Conference (July 7-8, 2016 - Boston, Massachusetts, USA).
Cole P
Drugs Today (Barc); 2016 Sep; 52(9):531-534. PubMed ID: 27883119
[TBL] [Abstract][Full Text] [Related]
49. Peptide-Based Treatment: A Promising Cancer Therapy.
Xiao YF; Jie MM; Li BS; Hu CJ; Xie R; Tang B; Yang SM
J Immunol Res; 2015; 2015():761820. PubMed ID: 26568964
[TBL] [Abstract][Full Text] [Related]
50. American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 1.
Croasdell G
IDrugs; 2010 Sep; 13(9):595-7. PubMed ID: 20799136
[TBL] [Abstract][Full Text] [Related]
51. HDAC Inhibitors--CHI's Third Annual Conference.
Rosato RR
IDrugs; 2010 Jan; 13(1):13-5. PubMed ID: 20024840
[TBL] [Abstract][Full Text] [Related]
52. BioPartnering North America--Spotlight on Canada.
Croydon L
IDrugs; 2010 Mar; 13(3):159-61. PubMed ID: 20191430
[TBL] [Abstract][Full Text] [Related]
53. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
[TBL] [Abstract][Full Text] [Related]
54. DNA fusion gene vaccines against cancer: from the laboratory to the clinic.
Stevenson FK; Rice J; Ottensmeier CH; Thirdborough SM; Zhu D
Immunol Rev; 2004 Jun; 199():156-80. PubMed ID: 15233733
[TBL] [Abstract][Full Text] [Related]
55. Perspectives in Lung Cancer--Third Asian-pacific Conference. 11-12 September 2009, Bangkok, Thailand.
Lopes Gde L
IDrugs; 2009 Nov; 12(11):689-91. PubMed ID: 19844853
[TBL] [Abstract][Full Text] [Related]
56. American Association for Cancer Research: potential target antigens for cancer immunotherapy. April 1-5, 2000, San Francisco, CA, USA.
Shankar G
Expert Opin Investig Drugs; 2000 Jun; 9(6):1419-24. PubMed ID: 11203451
[TBL] [Abstract][Full Text] [Related]
57. Vaccines for colorectal cancer and renal cell carcinoma.
Kabaker K; Shell K; Kaufman HL
Cancer J; 2011; 17(5):283-93. PubMed ID: 21952277
[TBL] [Abstract][Full Text] [Related]
58. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
59. Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis.
Yin X; Wang W; Zhu X; Wang Y; Wu S; Wang Z; Wang L; Du Z; Gao J; Yu J
Biochem Biophys Res Commun; 2015 Sep; 465(2):239-44. PubMed ID: 26253468
[TBL] [Abstract][Full Text] [Related]
60. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
